Transcriptomic analysis of melanoma cells extracted from different sites of the primary tumor
Автор: Aksenenko Maria B., Komina Anna V., Palkina Nadezhda V., Averchuk Anton S., Rybnikov Yury A., Dyhno Yury A., Ruksha Tatiana G.
Журнал: Сибирский онкологический журнал @siboncoj
Рубрика: Клинические исследования
Статья в выпуске: 4 т.17, 2018 года.
Бесплатный доступ
Introduction. Intratumor heterogeneity is a characteristic feature for most malignant tumors, including cutaneous melanoma. This property represents one of the main obstacles for effective targeted therapy, due to the different sensitivity to chemotherapeutic agents on various tumor cells subclones. Treatment of malignant tumors requires an individual approach to choose the most appropriate treatment regimen. The purpose of the study was to evaluate differences in melanoma tissue samples obtained from different parts of one patient’s primary tumor at the transcriptomic level. Material and Methods. Melanoma cell cultures obtained from both central and peripheral parts of the primary tumor of two patients were used in the study. Results. Subclones from different parts of the first patient’s tumor were similar, whereas the second patient demonstrated significant differences at the transcriptomic level (in 2953 transcripts out of 48226). In the cells of the central zone of the second patient’s tumor, an increase in mRNA of the genes encoding proteins associated with tumor-specific immune response, as well as ABC-family transport proteins and cytokine signaling molecules, were noted. In the cells from the peripheral area of the same tumor, a more intensive transcription of genes encoding extracellular matrix and inflammatory response proteins was observed. Taken all round, the differences between the subclones of the second patient’s cells were relevant to some signaling cascades playing a leading role in oncogenesis (MAPK, PI3K-Akt-mTOR, VEGFA-VEGFR2, etc.). Conclusion. The study allowed evaluation of differences between cancer cells within a tumor at the transcriptional level in order to search for further approaches to personalized melanoma therapy.
Melanoma, heterogeneity, transcriptome, microenvironment
Короткий адрес: https://sciup.org/140254201
IDR: 140254201 | DOI: 10.21294/1814-4861-2018-17-4-59-66
Список литературы Transcriptomic analysis of melanoma cells extracted from different sites of the primary tumor
- Hunter K.W., Amin R., Deasy S., Ha N.H., Wakefield L. Genetic insights into the morass of metastatic heterogeneity. Nat Rev Cancer. 2018 Apr; 18(4): 211-23. DOI: 10.1038/nrc.2017.126
- Gerlinger M., Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010 Oct 12; 103(8): 1139-43. DOI: 10.1038/sj.bjc.6605912
- Housman G., Byler S., Heerboth S., Lapinska K., Longacre M., Snyder N., Sarkar S. Drug resistance in cancer: an overview. Cancers (Basel). 2014 Sep 5; 6(3): 1769-92. DOI: 10.3390/cancers6031769
- Dagogo-Jack I., Shaw A.T. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018 Feb; 15(2): 81-94. DOI: 10.1038/nrclinonc.2017.166
- Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S., Gazdar A., Gray J.W. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006 Dec; 10(6): 515-27. DOI: 10.1016/j.ccr.2006.10.008